Jaime Avecillas, MD
Pulmonary Disease · Miami, FLNPI 1366409245
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $45,110 of the $70,309 with a category attached, or 64.2%. Boehringer Ingelheim accounts for 89.7% of it on its own, with 25 other manufacturers making up the rest. Among pulmonary disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 359 payments — averaging $195.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$63K
- Inspire Medical Systems, Inc.$1K
- Actelion Pharmaceuticals US, Inc.$1K
- GSK$912
- Mallinckrodt Hospital Products Inc.$854
- Insmed, Inc.$679
- plus $2K from 20 others
Across 79 payments — averaging $19,826 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$1.6M
What the payments were for
- Consulting fees$12,13617%
- Speaking & faculty fees$45,11064%
- Travel & lodging$2,8514%
- Food & beverage$10,07014%
- Education$1420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 110 | $63,051 |
| Inspire Medical Systems, Inc. | 13 | $1,316 |
| Actelion Pharmaceuticals US, Inc. | 33 | $1,217 |
| GSK | 55 | $912 |
| Mallinckrodt Hospital Products Inc. | 26 | $854 |
| Insmed, Inc. | 29 | $679 |
| AstraZeneca | 29 | $559 |
| Harmony Biosciences LLC | 9 | $418 |
| Verona Pharma, Inc. | 11 | $228 |
| Regeneron Healthcare Solutions, Inc. | 6 | $193 |
| Bayer | 8 | $184 |
| Sanofi | 6 | $144 |
| United Therapeutics Corporation | 4 | $88 |
| Mylan Specialty L.p. | 2 | $69 |
| Teva Pharmaceuticals USA, Inc. | 2 | $58 |
| Paratek Pharmaceuticals, Inc. | 2 | $43 |
| Lilly USA, LLC | 2 | $41 |
| Baxter Healthcare | 2 | $40 |
| Merck | 2 | $38 |
| Resmed Corp | 2 | $38 |
| Inogen, Inc. | 1 | $34 |
| Viatris Specialty LLC | 1 | $25 |
| Nabriva Therapeutics, PLC | 1 | $23 |
| Grifols USA, LLC | 1 | $21 |
| Phadia US Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$22,501
- Inspire$802
- UPTRAVI$355
- OPSUMIT$355
- Inspire Upper Airway Stimulation System$119
How this compares
$70,309 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 500 | $329,025 |
| OfevNintedanib Esylate | 13 | $168,955 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 150 | $102,473 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 187 | $74,661 |
| Breo ElliptaFluticasone/Vilanterol | 160 | $65,200 |
| NucalaMepolizumab | 12 | $45,026 |
| Spiriva RespimatTiotropium Bromide | 54 | $26,911 |
| SymbicortBudesonide/Formoterol Fumarate | 92 | $22,758 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 199 | $18,961 |
| Azelastine Hcl | 738 | $18,216 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 734 | $18,128 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $12,035 |
| Fluticasone Propionate | 1,017 | $11,178 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 43 | $8,118 |
| Atrovent HfaIpratropium Bromide | 14 | $7,995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta | $912 | $451,286695 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $63,051 | $270,527254 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $559 | $125,231242 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Miami
- Javier Perez FernandezMiami$496K
- Raul ValorMiami$232K
- Shirin ShafazandMiami$193K
- Michael HernandezMiami$153K
- Ignacio CendanMiami$140K
- Andres SosaMiami$91K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
- Anas HadehWeston$800K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.